denenicokin

Recombinant proteinexperimental

Clinical trial activity

10 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2004 (NCT00095108)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • denenicokin
  • denenicokin
  • denenicokin
  • il21
  • il-21
  • il-21
  • il-21
  • il21 protein, human
  • interleukin 21
  • interleukin-21
  • interleukin-21
  • interleukin 21 protein, human
  • recombinant human interleukin 21
  • ril-21
  • ril-21; recombinant human interleukin 21

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01629758Phase 1Jun 1, 2012Bristol-Myers Squibb
NCT01152788Phase 2Jun 1, 2010British Columbia Cancer Agency, Canadian Cancer Trials Group, University of Toronto
NCT00601861Phase 2Feb 13, 2008Novo Nordisk
NCT00523380Phase 2Oct 4, 2007Novo Nordisk
NCT00617253Phase 2Jul 12, 2007Novo Nordisk
NCT00514085Phase 2Jul 1, 2007Canadian Cancer Trials Group, University of Toronto
NCT00389285Phase 1/Phase 2 (Phase 2)Oct 1, 2006ZymoGenetics
NCT00347971Phase 1Jun 1, 2006ZymoGenetics
NCT00336986Phase 2Sep 1, 2004Novo Nordisk
NCT00095108Phase 1May 1, 2004ZymoGenetics
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Novo NordiskFor profit4412004
ZymoGeneticsFor profit3322004
Canadian Cancer Trials GroupAcademic/Hospital2212007
University of TorontoAcademic/Hospital2012007
Bristol-Myers SquibbFor profit1112012
British Columbia Cancer AgencyAcademic/Hospital1012010
6 organizations
Page 1 / 1